29 June 2012
Tacrolimus-induced nephrotoxicity and genetic variability: A review
Violette M.G.J. Gijsen, Parvaz Madadi, Marie-Pierre Dube, Dennis A. Hesselink, Gideon Koren, Saskia N. de WildtDOI: 10.12659/AOT.883229
Ann Transplant 2012; 17(2): 111-121
Abstract
Background: Calcineurin inhibition (CNI) is the mainstay of immunosuppressant therapy for most solid organ transplant patients. High tacrolimus levels are related with acute nephrotoxicity, but the relationship with chronic toxicity is less clear. Variation in disposition of tacrolimus is associated with genetic variation in CYP3A5. Hence, could genetic variation in CYP3A5 or other genes involved in tacrolimus disposition and effect be associated with a risk for tacrolimus-induced nephrotoxicity? To perform a review of the literature and to identify if genetic variation in CYP3A5 or other genes involved in tacrolimus disposition or effect may be associated with tacrolimus-induced nephrotoxicity and/or renal dysfunction in solid organ transplant recipients. Material/Methods: Pubmed/Medline, Embase and Google were searched from their inception till November 8th 2010 with the search terms ‘tacrolimus’, ‘genetics’, and ‘nephrotoxicity’ or ‘renal dysfunction’. References of relevant articles were screened as well. Results: We identified 13 relevant papers. In kidney recipients, associations between donor ABCB1, recipient CCR5 genotype and tacrolimus-induced nephrotoxicity were found. CYP3A5 genotype studies in kidney recipients yielded contradictory results. In liver recipients, a possible association between recipient ACE, CYP3A5, ABCB1 and CYP2C8 genetic polymorphisms and tacrolimus-induced nephrotoxicity was suggested. In heart recipients, TGF-β genetic polymorphisms were associated with tacrolimus-induced nephrotoxicity. The quality of the studies varied considerably. Conclusions: Limited evidence suggests that variation in genes involved in pharmacokinetics (ABCB1 and CYP3A5) and pharmacodynamics (TGF-β, CYP2C8, ACE, CCR5) of tacrolimus may impact a transplant recipients’ risk to develop tacrolimus-induced nephrotoxicity across different transplant organ groups.
Keywords: Pharmacogenetics, Transplant, Tacrolimus, nephrotoxicity, CYP3A5, ABCB1, TGF-β
In Press
Original article
Prognostic Nutritional Index Trajectories Predict Kidney Function in Kidney Transplant Recipients: A Latent...Ann Transplant In Press; DOI: 10.12659/AOT.947388
Original article
Impact of Preoperative Treatment on Donor Hepatic Steatosis in Living Donor Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.947772
Original article
Effects of Donor-Recipient Race Matching on Kidney Transplant SurvivalAnn Transplant In Press; DOI: 10.12659/AOT.947720
Most Viewed Current Articles
03 Jan 2023 : Original article 6,972
Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and...DOI :10.12659/AOT.938467
Ann Transplant 2023; 28:e938467
15 Aug 2023 : Review article 6,961
Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ TransplantationDOI :10.12659/AOT.939750
Ann Transplant 2023; 28:e939750
16 May 2023 : Original article 6,731
Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections ...DOI :10.12659/AOT.939258
Ann Transplant 2023; 28:e939258
28 May 2024 : Original article 6,151
Effect of Dexmedetomidine Combined with Remifentanil on Emergence Agitation During Awakening from Sevoflura...DOI :10.12659/AOT.943281
Ann Transplant 2024; 29:e943281